COST-Bl Working Party on Population Approaches: L.Aarons(1), L.P.Balant(2), F.Mentre(3), P.L.Morselli(4), M.Rowland(1), J.-L.Steimer(5), and S.Vozeh(6) Population Approaches in Drug Development: Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software
|
Carl Peck, Tom Ludden Pitfalls in Retrospective Analysis in Search of Concentration-Effect Relationships
|
Mats O. Karlsson(1,3), Stuart L. Beal(2) and Lewis B. Sheiner(1,2) Three New Residual Error Models For Population PK/PD Analyses
|
J.R. Wade, PhD(1,2), S.L. Beal PhD(2) and N.C. Sambol, PharmD(2) Interaction between structural, statistical and covariate models in population pharmacokinetic analysis
|
Jaap W Mandema(1), Davide Verotta(2), and Lewis B Sheiner(2,3) Diagnostics For Nonlinear Mixed Effects Models
|
Y. Merlé and F. Mentré Comparison of Bayesian Optimal Designs with Respect to Variations of the Population Characteristics. For a Pharmacokinetic and a Pharmacodynamic Model
|
Constantin Efthymiopoulos, PhD, Valérie Cosson, Pharm D, Alan Bye, PhD The Use of NONMEM in Interspecies Allometric Scaling
|
Alan V. Boddy, Michael Cole, Peng Bin, Andrew D.J. Pearson and David R. Newell A limited sampling model with Bayesian estimation to determine carboplatin pharmacokinetics in paediatrics
|
E Chatelut(1,2), V Brunner(1), C Chevreau(1), A Pujol(1), H Roché(1), V Paschel(1), G Houin(2), R Bugat(1,2), P Canal(1) Carboplatin Population Pharmacokinetics
|
Dr Alan Bye, Head of Clinical Pharmacokinetics Department Issues and Suggested Solutions in Drug Development
|
René Bruno, N. Vivier, J.C. Vergniol, G. Montay and L.B. Sheiner(1) A Validation For A Population Pharmacokinetic Model For Docetaxel
|
Andrew P. Grieve Combining Studies : Opportunities And Pitfalls
|
Jean-Louis Steimer, Marie-Eve Ebelin Implementation of pharmacometric approaches into clinical drug development ? A prospective view
|
Lewis B. Sheiner, MD The Future Place Of Modeling In Drug Development
|
Jon Wakefield Review of methods
|